Intestinal Immunity and Gut Microbiota in Atherogenesis

DOI 機関リポジトリ (HANDLE) Web Site PubMed 被引用文献3件 参考文献42件 オープンアクセス
  • Yamashita Tomoya
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine

書誌事項

公開日
2017
資源種別
journal article
DOI
  • 10.5551/jat.38265
公開者
一般社団法人 日本動脈硬化学会

この論文をさがす

説明

<p>Atherosclerosis is a chronic inflammatory disease. Interventions targeting the inflammatory process could provide new strategies for preventing atherosclerotic cardiovascular diseases (CVD). Previously, we have reported that oral administration of anti-CD3 antibodies, or active vitamin D3, reduced atherosclerosis in mice via recruiting regulatory T cells and tolerogenic dendritic cells to the gut-associated lymphoid tissues. From this, it is reasonable to propose that the intestine could be a novel therapeutic target for prevention of atherosclerotic CVD. Recently, the association between cardio-metabolic diseases and gut microbiota has attracted increased attention. Gut microbiota, reported to be highly associated with intestinal immunity and metabolism, were shown to aggravate CVD by contributing to the production of trimethylamine-N-oxide (TMAO), a pro-atherogenic compound. We have also previously investigated the relationship between patient susceptibility to coronary artery disease (CAD) and gut microbiota. We found that the order Lactobacillales was significantly increased and the phylum Bacteroidetes was decreased in CAD patients compared with control patients. In this review article, we discuss the evidence for the relationship between the gut microbiota and cardio-metabolic diseases, and consider the gut microbiota as new potential diagnostic and therapeutic tool for treating CVD.</p>

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (42)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ